'Breakthrough' status granted to Aimmune's peanut allergy drug
This article was originally published in Scrip
Executive Summary
The FDA has granted breakthrough therapy designation (BTD) to Aimmune Therapeutics' investigational oral immunotherapy for peanut allergy, known as AR101.
You may also be interested in...
Aimmune’s Peanut Allergy Immunotherapy Brings Safety Concerns To US FDA Panel
Palforzia was associated with a higher rate of adverse events, systemic allergic reactions, eosinophilic esophagitis and epinephrine use in controlled clinical trials; Allergenic Products Advisory Committee will weigh approval for patients ages 4-17 years with confirmed peanut allergy diagnosis.
Keeping Track: A Long-Awaited Approval For Generic EpiPen, Cancer Product Labels Expand And Constrict
The latest drug development news and highlights from our US FDA Performance Tracker.
Aimmune Accelerates Commercial Planning For Peanut Allergy Drug
Even better than expected efficacy and safety in the Phase III PALISADE trial puts Aimmune on track to file its BLA for peanut protein capsule AR101 by the end of 2018.